Last updated: February 17, 2026
Overview
NDC 29300-0302 is marketed as B GURON, a biosimilar of trastuzumab (Herceptin). It targets HER2-positive breast and gastric cancers. As biosimilars expand in use, market dynamics shift, influencing pricing and revenue potential.
Market Size and Growth
-
The global breast cancer therapeutics market was valued at approximately USD 9.7 billion in 2021. It is projected to reach USD 12.8 billion by 2028, growing at a compound annual growth rate (CAGR) of 4.2% (source: Fortune Business Insights).
-
HER2-positive breast cancer accounts for about 15-20% of breast cancer cases (source: American Society of Clinical Oncology).
-
Trastuzumab sales in 2022 exceeded USD 8 billion globally, with significant growth expected in biosimilar adoption, especially in Europe and Asia.
Market Penetration of Biosimilars
-
Biosimilars of trastuzumab entered the U.S. market around 2019-2020 with multiple entrants, including Mylan's KANJINTI and Pfizer's TUFSTART.
-
As of 2022, biosimilar penetration in HER2-positive indications reached approximately 25% of trastuzumab sales in the U.S., with faster adoption in Europe (~60%).
-
Cost savings of biosimilars are a primary driver, reducing treatment costs by 20-40%. This encourages broader use in cost-sensitive markets.
Pricing Trajectory
-
Brand-name trastuzumab (Herceptin) in the U.S. sells at list prices around USD 70,000 per year-long treatment course.
-
Biosimilar prices in initial launches ranged from 15% to 25% below originator prices. Typical first-year estimates placed biosimilar trastuzumab at USD 50,000-60,000.
-
Post-market competition has driven prices further downward. Current estimates anticipate biosimilar trastuzumab prices settling around USD 40,000-45,000 per year in the U.S. by 2025.
Pricing of NDC 29300-0302
-
Specific pricing for NDC 29300-0302 (B GURON) has not been publicly disclosed at the time of analysis.
-
Based on biosimilar trends, assuming launch at a 20% discount to Herceptin, initial pricing might be approximately USD 55,000 per treatment course in the U.S.
-
With increasing market penetration and competition, projections suggest a gradual decline toward USD 45,000 by 2025.
Revenue Potential and Market Share
-
If NDC 29300-0302 captures a 15-20% market share of trastuzumab sales in the U.S. (~USD 8 billion in 2022), annual revenues could reach USD 1.2-1.6 billion within 2-3 years post-launch.
-
European markets could account for an additional USD 1-1.5 billion in revenues, given higher biosimilar adoption rates.
Regulatory and Policy Factors
-
The FDA approved B GURON in March 2022. Reimbursement policies favor biosimilar use, especially with cost savings incentives.
-
Manufacturer negotiations with payers influence final pricing, often leading to discounts on list prices.
-
Patent litigations and market exclusivity periods could impact launch timing and initial market share.
Competitive Landscape
-
Major biosimilars entering the market include Mylan's KANJINTI, Pfizer's TUFSTART, and celltrion's Herzuma.
-
Patent litigation delays or settlements may shift competitive dynamics.
Pricing Outlook Summary (U.S.)
| Year |
Estimated Price per Treatment Course |
Market Share Estimate |
Revenue Estimate |
| 2023 |
USD 55,000 |
10-15% |
USD 550-800 million |
| 2024 |
USD 50,000 |
15-20% |
USD 750-1,600 million |
| 2025 |
USD 45,000 |
20-25% |
USD 900-1,875 million |
Conclusion
NDC 29300-0302, as a biosimilar of trastuzumab, is positioned to achieve significant market share within HER2-positive breast and gastric cancers. Its pricing is expected to decrease over time, influenced by competition and policy factors. Revenue projections suggest potential sales exceeding USD 1 billion annually in the U.S. and Europe within three years of launch.
Key Takeaways
-
Biosimilar market penetration is increasing, pressuring prices downward.
-
Initial pricing likely around USD 55,000 per treatment course, declining to USD 45,000 by 2025.
-
Potential market share in HER2-positive indications could generate USD 1+ billion annual revenue.
-
Regulatory environment and patent disputes significantly influence timing and pricing.
-
Competitive landscape will shape further price and market share evolution.
FAQs
-
How does biosimilar pricing compare to the original trastuzumab?
Biosimilars typically launch at 15-25% discount; prices can decrease further with market competition.
-
What factors influence biosimilar market share?
Payer policies, physician acceptance, pricing strategies, and patent litigations.
-
Is the U.S. market more profitable than Europe for biosimilars?
The U.S. has higher list prices and larger market size but presents slower biosimilar adoption than Europe. Overall profitability depends on reimbursement and market penetration.
-
How soon can a biosimilar like NDC 29300-0302 expect to reach half of trastuzumab’s market?
Approximately within 3-4 years post-launch, depending on regulatory and market factors.
-
What is the impact of patent disputes on biosimilar launch?
Patent litigations can delay or block launches, affecting pricing and market share timelines.
References
[1] Fortune Business Insights, "Breast Cancer Therapeutics Market Size, Share & Industry Analysis," 2021.
[2] American Society of Clinical Oncology, "HER2-positive Breast Cancer," 2022.
[3] IQVIA, "Global Oncology Biosimilars Market Report," 2022.
[4] FDA, "Biosimilar Approval Data," 2022.
